Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Organisation › Details

Navamedic ASA

Navamedic is a Norwegian speciality pharmaceutical company focusing on the development and production of glucosamine HCl (hydrochloride) based medicines. Glucosamine is a generic active ingredient which relieves pain and improves function in patients with mild to moderate osteoarthritis. The product has a favourable safety profile. Osteoarthritis is a chronic disease which affects a large and growing share of the world`s population. Navamedic aims to become a leading company in the glucosamine industry, with a competitive advantage in proprietary production technology. Navamedic`s product Glucomed has been approved across 25 EU/EEA states by European Medicines Agency (EMEA), as the first and only glucosamine based medicine against osteoarthritis. The product is marketed under different brand names in some markets depending on local market adaptations. The products is sold through a network of sales, marketing and distribution partners. *


Period Start 2007-10-09 existent
  Group Navamedic (Group)
Product Industry pharmaceutical
Region Region Lysaker
  Country Norway
  Street 13 C Vollsveien
  City 1327 Lysaker
  Tel +47-67-112540
    Address record changed: 2018-07-24
Basic data Employees n. a.
    * Document for �About Section�: 
Record changed: 2018-08-22


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Navamedic (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Made Without Love 650x80px

» top